Pure Global
NCT06346340

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy
Bausch & Lomb Incorporated·Phase 4·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Eye
Drug/Device/Intervention
Miebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Bausch & Lomb Incorporated
Location
Laguna Hills,Petaluma,Largo,Saint Louis,Somersworth, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Mar 11, 2024
End date
Sep 01, 2024
Enrollment
100 participants
Primary outcome

Mean difference between absolute deviations from predicted refractive error in the study eye.

Summary

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative
 Biometry/ Keratometry and Postoperative Refractive Accuracy

ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06346340
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06346340 through Pure Global AI's free database. This Phase 4 trial is sponsored by Bausch & Lomb Incorporated and is currently Recruitment Completed. The study focuses on Dry Eye. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.